miRNA, transcriptional regulation and cognitive decline

dc.contributor.authorFischer, Andre
dc.contributor.authorSananbenesi, Farahnaz
dc.contributor.authorNho, Kwangsik
dc.contributor.authorManfred Krüger, Dennis
dc.contributor.authorShaw, Leslie M.
dc.contributor.authorSaykin, Andrew J.
dc.contributor.authorDelalle, Ivana
dc.contributor.departmentRadiology and Imaging Sciences, School of Medicine
dc.date.accessioned2025-02-24T13:28:54Z
dc.date.available2025-02-24T13:28:54Z
dc.date.issued2025-01-03
dc.description.abstractBackground: Despite significant advancements in the development of blood biomarkers for AD, challenges persist due to the complex interplay of genetic and environmental risk factors in AD pathogenesis. Epigenetic processes, including non‐coding RNAs and especially microRNAs (miRs), have emerged as important players in the molecular mechanisms underlying neurodegenerative diseases. MiRs have the ability to fine‐tune gene expression and proteostasis, and microRNAome profiling in liquid biopsies is gaining increasing interest since changes in miR levels can indicate the presence of multiple pathologies. We have profiled blood samples via smallRNA sequencing for 1056 individuals of the DELCODE and 847 individuals of the ANDI cohort. Methods: We profiled blood samples via smallRNA sequencing for 1056 individuals of the DELCODE (German Longitudinal Cognitive Impairment and Dementia Study) and 847 individuals of the ANDI (Aging and Dementia in the Community) cohort, consisting of individuals diagnosed with SCD, MCI, AD, or control. Results: By applying differential expression, WGCNA, as well as linear and non‐linear machine learning approaches, we identify microRNA signatures that can help identify patients at distinct stages of disease progression, as well as signatures that can predict the course of the disease. These data are compared with phenotyping data, such as cognitive function and ATN biomarkers. We will also discuss the role of other non‐coding RNAs besides microRNAs and provide a framework for developing RNA‐based point‐of‐care assays.
dc.eprint.versionFinal published version
dc.identifier.citationFischer A, Sananbenesi F, Nho K, et al. miRNA, transcriptional regulation and cognitive decline. Alzheimers Dement. 2025;20(Suppl 1):e083400. Published 2025 Jan 3. doi:10.1002/alz.083400
dc.identifier.urihttps://hdl.handle.net/1805/45957
dc.language.isoen_US
dc.publisherWiley
dc.relation.isversionof10.1002/alz.083400
dc.relation.journalAlzheimer's & Dementia
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.sourcePMC
dc.subjectBlood biomarkers
dc.subjectAlzheimer's disease
dc.subjectGenetic risk factors
dc.subjectEnvironmental risk factors
dc.subjectAD pathogenesis
dc.titlemiRNA, transcriptional regulation and cognitive decline
dc.typeAbstract
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Fischer2025miRNA-CCBY.pdf
Size:
91.28 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: